MetaCap

Ovid Therapeutics Inc. (OVID)

NASDAQ: OVIDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.20-0.14 (-5.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OVID stock chart

Technical analysis

Key statistics

All statistics
Market cap
$415.21M
EPS (TTM)
-$0.15
52-week range
1.26 – 3.11
Day range
2.17 – 2.33
Volume / Avg
2.83M / 1.98M
Beta
—

52-week range

$1.26$3.11

OVID stock today

Ovid Therapeutics (OVID) closed at $2.20 on Nov 20, down 5.98% (-$0.14), versus the S&P 500's 3.70% decline. At this level, OVID sits in the middle of its 52-week range of $1.26 to $3.11: 29.1% below the high, set on Apr 9, 2026 and 74.6% above the low. OVID is up 35.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 57.1%.

Ovid Therapeutics has posted a net loss over the last twelve months (EPS of -$0.15), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Ovid Therapeutics

Company profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Margaret Alexander
Headquarters
New York, NY
Employees
23
IPO year
2017
Website
ovidrx.com

Financial highlights

Full financials

In fiscal 2025, Ovid Therapeutics generated $7.3 million in revenue, up 1181.3% from fiscal 2024, its 2nd consecutive year of revenue growth. Ovid Therapeutics reported a net loss of $17.4 million, compared with a loss of $26.4 million a year earlier. Operating margin was -585.2%.

Ovid Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$7.25M$566.00K$392.00K$1.50M$208.38M
Growth+1181.27%+44.39%-73.91%-99.28%+1551.57%
Net income$-17.41M$-26.43M$-52.34M$-54.17M$122.83M
EPS (diluted)——$-0.74$-0.77$1.76

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$6.15+179.55%

  • Strong buy 0
  • Buy 13
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.10 vs $-0.08
Surprise
-25.00%

OVID news

All OVID news

Ovid Therapeutics peers

Health Care sector
OVID peer companies
CompanyPrice% ChgMarket capCompare
CRMDCorMedix Inc.5.27+3.74%$419.16Mvs OVID
PRTAProthena Corporation plc8.22-2.14%$422.10Mvs OVID
ARVNArvinas Inc.6.46-4.15%$423.03Mvs OVID
EOLSEvolus Inc.6.52-6.86%$431.55Mvs OVID
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs OVID
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs OVID
OCSOculis Holding AG7.06-5.11%$393.35Mvs OVID
AVTXAvalo Therapeutics Inc.6.76+0.15%$390.88Mvs OVID

Indexes, lists and sector

Ovid Therapeutics stock FAQ

What is Ovid Therapeutics's stock price today?

OVID last traded at $2.20 as of Nov 20, 4:00 PM EST, down 5.98% on the day. Prices are delayed at least 15 minutes.

Who is Ovid Therapeutics's CEO?

Ms. Margaret Alexander is the chief executive officer of Ovid Therapeutics Inc., which has about 23 employees.

What is the OVID 52-week high?

The 52-week high for OVID is $3.11 and the 52-week low is $1.26. The stock is currently 29.1% below its high.

Compare OVID